Group 1 - Immuneering Corporation (NASDAQ:IMRX) is recognized as a promising fast money stock, with analysts at Mizuho maintaining an 'Outperform' rating and a price target of $10, indicating a potential increase of approximately 43% [1][2] - The company reported positive modified 9-month survival data from its Phase 2a trial of atebimetinib (atebi) in first-line pancreatic cancer patients, with results from 34 patients showing overall survival and progression-free survival that exceeded both standard treatments and the firm's expectations [2][3] - The drug atebimetinib is highlighted for its potential to become a leading treatment for pancreatic cancer, with improved durability compared to previous data, reinforcing confidence in the drug's prospects and the company's future [3][4] Group 2 - Immuneering Corporation is a clinical-stage oncology company based in Massachusetts, founded in 2008, focused on developing innovative treatments for a wide range of cancer patients [4]

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up. “These exciting results were first announced in our press rel ...

Core Viewpoint - Immuneering Corporation has appointed Dr. Thomas J. Schall as Chairman of the Board of Directors, which is seen as a strategic move to advance the company's oncology programs, particularly the lead product candidate, atebimetinib [1][4]. Company Overview - Immuneering is a clinical-stage oncology company focused on developing a new category of cancer medicines known as Deep Cyclic Inhibitors. The lead product candidate, atebimetinib, is designed to improve durability and tolerability for patients with MAPK pathway-driven tumors, including pancreatic cancer [5]. Leadership Background - Dr. Schall has over 30 years of experience in drug discovery and development, previously serving as the founder and CEO of ChemoCentryx, where he led the development of Tavneos®, a therapy for ANCA-associated vasculitis. ChemoCentryx was acquired by Amgen in 2022 for nearly $4 billion [2][4]. Strategic Importance - The appointment of Dr. Schall is considered pivotal as Immuneering prepares for late-stage development, regulatory filings, and commercialization of its therapies. His expertise in navigating the complex path from early science to market is expected to be critical for the company's success [3][4]. Upcoming Developments - Immuneering plans to announce updated data from its ongoing phase 2a study of atebimetinib in pancreatic cancer patients on September 25, with further presentations at the Pancreatic Cancer Action Network Annual Scientific Summit on September 28 [3].

Core Insights - Immuneering Corporation plans to announce updated overall survival data for first-line pancreatic cancer patients treated with atebimetinib + mGnP on September 25, 2025, following a 9-month median follow-up [1][3][6] - The company has reported a 94% overall survival (OS) rate at 6 months for patients treated with atebimetinib + mGnP, compared to 67% OS for standard care, which drops to approximately 47% by 9 months [3][6] - Immuneering is developing a new category of cancer medicines called Deep Cyclic Inhibitors, with atebimetinib being the lead candidate currently in a Phase 2a trial [4][6] Company Plans and Presentations - An investor call is scheduled for 8 a.m. ET on September 25, 2025, to discuss the updated data [1][6] - Immuneering will present a poster on "Atebimetinib + mGnP: Overall Survival and Safety in First Line Pancreatic Cancer Patients" at the PanCAN Scientific Summit on September 28, 2025 [6] - The company will also present preclinical data on Deep Cyclic Inhibitors at the 7th RAS-Targeted Drug Development Summit on September 17, 2025 [5][6]

Core Insights - Immuneering Corporation has entered into a definitive securities purchase agreement for a private placement expected to yield approximately $25 million in gross proceeds before fees and expenses [1] - The company is focused on developing a new category of cancer medicines called Deep Cyclic Inhibitors, with its lead product candidate, atebimetinib, currently in a Phase 2a trial for pancreatic cancer [2][5] - The recent data from the Phase 2a trial shows a 94% overall survival rate at 6 months for patients treated with atebimetinib in combination with mGnP, significantly higher than the 67% observed in the standard of care [2] Financing Details - The private placement involves the sale of 6,329,113 unregistered shares of Class A common stock at a price of $3.95 per share, representing a 15% premium over the last reported closing price [2] - Investors will also receive purchase warrants for an aggregate of 2,848,096 shares at an exercise price of $5.50 per share, with a five-year exercisability period following registration for resale [2] Company Overview - Immuneering is a clinical-stage oncology company dedicated to improving the survival of cancer patients through innovative treatments [5] - The company is developing atebimetinib as an oral, once-daily treatment aimed at enhancing durability and tolerability for MAPK pathway-driven tumors, including pancreatic cancers [5]

Core Viewpoint - Immuneering Corporation is advancing its clinical-stage oncology product, atebimetinib, showing promising overall survival (OS) and progression-free survival (PFS) data in first-line pancreatic cancer patients, with plans for a pivotal trial in 2026 [1][2][5]. Financial Highlights - As of June 30, 2025, the company reported cash and cash equivalents of $26.4 million, down from $36.1 million at the end of 2024 [6]. - Research and development (R&D) expenses for Q2 2025 were $10.5 million, slightly lower than $10.7 million in Q2 2024 [7]. - General and administrative (G&A) expenses remained stable at $4.3 million for both Q2 2025 and Q2 2024 [8]. - The net loss for Q2 2025 was $14.4 million, or $0.40 per share, compared to a net loss of $14.1 million, or $0.47 per share, in Q2 2024 [8][16]. Clinical Development Updates - The ongoing Phase 2a trial of atebimetinib in combination with modified Gemcitabine/nab-paclitaxel (mGnP) has shown a 94% OS at 6 months in first-line pancreatic cancer patients (N = 34) [4][5]. - The company plans to share updated OS and PFS data from the trial in Q3 2025, earlier than previously indicated [4]. - A composition of matter patent for atebimetinib was granted, expected to provide exclusivity until 2042, with potential extensions [4][5]. Future Milestones - Immuneering aims to initiate a pivotal, randomized trial of atebimetinib in combination with mGnP in first-line pancreatic cancer in 2026 [12]. - The company is preparing for regulatory feedback on pivotal study plans in Q4 2025 [12]. Patient Outcomes - A pancreatic cancer patient in the third-line setting has been on atebimetinib monotherapy for over 18 months, showing a 34% reduction in target lesions and a 96% reduction in peak CA 19-9 levels [5].

Core Insights - Immuneering has received a composition of matter patent for atebimetinib, a deep cyclic inhibitor of MEK, which is crucial in cancer signaling pathways [1][3][5] - The Phase 2a study shows that first-line pancreatic cancer patients treated with atebimetinib plus chemotherapy have a 94% probability of surviving 6 months, significantly higher than the 67% survival rate with standard chemotherapy [2] - The patent for atebimetinib is expected to provide exclusivity until August 2042, with potential for extension, supporting the company's strategy to maximize its therapeutic potential across various cancers [3][5][8] Company Overview - Immuneering is a clinical-stage oncology company focused on developing therapies that improve patient outcomes and quality of life [6] - The lead product candidate, atebimetinib, is designed to enhance durability and tolerability in treating MAPK pathway-driven tumors, including pancreatic cancer [6] - The company plans to explore atebimetinib in combination with other therapies for various cancer types [5][9] Intellectual Property Strategy - The granted patent validates the innovative approach of Immuneering and secures key intellectual property for atebimetinib [5] - Additional patent applications are pending, with expiration expected into 2044, further strengthening the company's intellectual property portfolio [8]

Immuneering Conference Call Summary Company and Industry - **Company**: Immuneering - **Industry**: Oncology, specifically focused on pancreatic cancer treatment Core Points and Arguments 1. **Goal of Treatment**: Immuneering aims to help cancer patients live longer, with a focus on controlling cancer as a chronic condition rather than solely curing it [4][5][6] 2. **Focus on Durability and Tolerability**: The company prioritizes durability (long-term survival) and tolerability (minimizing side effects) in its treatment approach [7][9][10] 3. **Atebimetinib**: The drug, an oral MEK inhibitor, is being tested in a Phase IIa trial for first-line pancreatic cancer, showing promising results in terms of durability and tolerability [12][13] 4. **Patient Population**: The trial focuses on first-line pancreatic cancer patients, where the need for effective treatments is critical due to high mortality rates [14] 5. **Survival Rates**: The median overall survival has not yet been reached, with a reported 94% overall survival at six months for patients treated with atebimetinib plus modified gemcitabine and nab-paclitaxel [15][17] 6. **Comparison to Standard Care**: The standard care for pancreatic cancer (gemcitabine and nab-paclitaxel) has a six-month survival rate of only 67%, highlighting the effectiveness of atebimetinib [16][17] 7. **Progression-Free Survival**: The study reports a 72% progression-free survival at six months, significantly higher than the 43% benchmark for standard care [27][28] 8. **Response Rates**: The overall response rate for the treatment is 39%, compared to 23% for standard care, with a disease control rate of 81% [29][30] 9. **Adverse Events**: The treatment has shown a favorable safety profile, with zero grade three or higher adverse events in six out of eleven categories compared to standard therapies [36][37] 10. **Patient Quality of Life**: The tolerability of the treatment is linked to improved quality of life, with patients experiencing fewer side effects and even weight gain [84][90] Additional Important Content 1. **Mechanism of Action**: Immuneering's approach involves deep cyclic inhibition of the MAP kinase pathway, allowing for better control of tumor growth and reduced resistance development [60][66] 2. **Future Plans**: The company plans to initiate a pivotal study in 2026 to further evaluate the efficacy of atebimetinib in combination with standard care [58][79] 3. **Broader Applicability**: While the current focus is on pancreatic cancer, the MAP kinase pathway's relevance extends to other cancers, indicating potential for future treatments in various oncology settings [72][77] 4. **Competitive Landscape**: Immuneering positions itself as a leader in first-line pancreatic cancer treatment, emphasizing its unique combination approach and superior tolerability compared to competitors [102][106] This summary encapsulates the key points discussed during the Immuneering conference call, highlighting the company's innovative approach to treating pancreatic cancer and its promising clinical results.

Clinical Trial Results of Atebimetinib - Atebimetinib + mGnP in first-line pancreatic cancer (1L PDAC) showed a 6-month Overall Survival (OS) of 94% in a Phase 2a trial (N=34)[18, 21] - The same combination also demonstrated a 6-month Progression-Free Survival (PFS) of 72%[24, 27] - The Overall Response Rate (ORR) for Atebimetinib + mGnP in 1L PDAC was 39% (14/36), and the Disease Control Rate (DCR) was 81% (29/36)[30] - Grade ≥ 3 Neutropenia adverse event incidence was 15%, Fatigue was 3%, Diarrhea was 0%, Sensory Neuropathy was 0%, Leukopenia was 0%, Vomiting was 3%, Febrile Neutropenia was 0%, Thrombocytopenia was 0%, Anemia was 18%, Hypokalemia was 3%, Nausea was 0%[35] Patient Characteristics - The median age of patients in the Atebimetinib + mGnP Phase 2a trial was 69 years, with 65% of patients being 65 years or older[37] Mechanism and Rationale - Atebimetinib targets the MAPK pathway with Deep Cyclic Inhibition (DCI) to improve durability and tolerability[71, 81] - Approximately 97% of pancreatic cancers are driven by the MAPK pathway[70] Future Plans - The company plans to initiate a pivotal study in 2026 for atebimetinib in 1L pancreatic cancer[81]